Propagating Peptides With Peptilogics' Jonathan Steckbeck, Ph.D.
Business Of Biotech
00:00
The Future of Antimicrobial Peptides
We're mostly focused on the cedar side. Who regulates peptides at the FDA? How's that handle from regulatory? So it's an interesting area. I get pitches all the time from companies that, you know, sometimes it's super clear to make the determination not to fit. Other times, not so much. We engineered 206. It's a 24 residue peptide, only natural amino acids, all L, no special modifications. And it's sequenced in a specific way to give us the activity characteristics that we want but to remove any of that potential to kickstart an inflammatory response. The data there were good. That's when I started the company to really put that through
Transcript
Play full episode
